Skip to main content

Table 1 Baseline Characteristics

From: Impact of pharmacist-conducted anticoagulation patient education and telephone follow-up on transitions of care: a randomized controlled trial

Variable Pharmacist-counseled
n = 100
Standard of care
n = 100
P-value
Sex    0.669
 Male 46 43  
 Female 54 57  
Age (Mean in years, +/− SD) 74.69 +/−  12.09 73.15+/−  14.74 0.420
Weight (Mean in Kg, +/− SD) 75.52 +/−  18.39 73.60 +/−  17.83 0.465
Smoker 27 26 1.000
Allergic to one or more drugs 22 14 0.141
Creatinine clearance closest to the date of prescribing    0.541
  < 15 mL/min 2 1  
 15 - < 30 mL/min 5 10  
 30 - 50 mL/min 21 19  
  > 50 mL/min 51 61  
Insurance type    0.072
 Private 37 23  
 Public 37 39  
 None (self) 26 5  
Indication for anticoagulation    0.236
 Atrial fibrillation 79 70  
 VTE treatment 8 11  
 Aortic valve replacement 7 11  
 Mitral valve replacement 4 7  
Antiplatelet use upon admission    0.431
 Aspirin 80–100 mg 17 19  
 Aspiring 162–325 mg 2 0  
 Clopidogrel 75 mg 5 3  
 Dual antiplatelet 1 4  
Anticoagulant prescribed upon discharge    0.006
 Vitamin K antagonist 33 53  
 DOAC 67 47  
DOAC prescribed upon discharge
 Apixaban 15 3 0.005
 Dabigatran 12 15 0.535
 Rivaroxaban 40 29 0.102
HAS-BLED risk score (Mean +/− SD) 2.26 +/− 1.3 2.23 +/− 1.05 0.882
Past medical history
 Hypertension 71 68 0.645
 Heart failure 34 20 0.026
 Chronic kidney disease 13 12 0.831
 Cancer 13 15 0.684
 History of bleeding 8 5 0.390
 History of gastrointestinal bleeding 6 4 0.516
  1. Abbreviations: SD Standard deviation, VTE Venous thromboembolism, DOAC Direct oral anticoagulant
\